Abstract:
|
This presentation discusses regulatory and statistical issues with subgroup analysis in regulatory decision making, for medical products ranging from therapeutic treatments to companion diagnostics. Such issues include interpretation and reporting of completed clinical trials and design of new studies where subgroup differences are expected.
|